Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Operating Income (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Operating Income for 3 consecutive years, with -$10.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Income fell 6.85% to -$10.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$47.0 million, a 19.83% decrease, with the full-year FY2024 number at -$47.4 million, down 66.68% from a year prior.
  • Operating Income was -$10.0 million for Q3 2025 at Mereo BioPharma, up from -$10.5 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$811000.0 in Q2 2023 to a low of -$15.3 million in Q4 2024.
  • A 3-year average of -$9.8 million and a median of -$10.0 million in 2025 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: crashed 1480.02% in 2024, then increased 18.07% in 2025.
  • Mereo BioPharma's Operating Income stood at -$7.1 million in 2023, then plummeted by 114.3% to -$15.3 million in 2024, then soared by 34.44% to -$10.0 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Operating Income are -$10.0 million (Q3 2025), -$10.5 million (Q2 2025), and -$11.2 million (Q1 2025).